Data from Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

MLA

Jeeyun Lee, et al. Data from Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6530478.

APA

Jeeyun Lee, Emma Dean, Andrew J. Pierce, Iwanka Kozarewa, Won Ki Kang, Ho Yeong Lim, Young Suk Park, Joon Oh Park, Se Hoon Park, Jung Yong Hong, Alienor Berges, Itziar Irurzun-Arana, Sophie Willis, Claire Smith, Kyoung-Mee Kim, Heejin Cho, Arsene-Bienvenu Loembé, Peter Mortimer, Simon A. Smith, & Seung Tae Kim. (2023). Data from Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. https://doi.org/10.1158/1078-0432.c.6530478

Chicago

Jeeyun Lee, Emma Dean, Andrew J. Pierce, Iwanka Kozarewa, Won Ki Kang, Ho Yeong Lim, Young Suk Park, et al. 2023. “Data from Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer,” March. doi:10.1158/1078-0432.c.6530478.